Skip to main content
Uni-Bio Science Group Ltd logo

Uni-Bio Science Group Ltd — Investor Relations & Filings

Ticker · 690 ISIN · KYG9198H1406 HKEX Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-03-27 Earnings Release
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Ltd

https://www.uni-bioscience.com/

Uni-Bio Science Group Ltd. is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative biological and chemical pharmaceutical products. The company specializes in regenerative medicine, with a primary focus on developing therapeutics for bone, muscle, skin, and tissue regeneration. Key application areas include osteoporosis, complex wound healing, medical aesthetics, and ocular conditions such as corneal injury and macular degeneration. The company also explores novel treatments in otolaryngology (ENT) and aesthetic skincare. Its R&D is supported by proprietary technology platforms, including an advanced microprotein manufacturing system (ECO-KSFA®) and an intelligent hydrogel platform for tissue engineering. These platforms facilitate the development of therapies utilizing growth factors and stem cell technology to address degenerative diseases and injuries.

Recent filings

Filing Released Lang Actions
Uni-Bio Science Group Limited Announces 2025 Annual Results
Earnings Release Classification · 95% confidence The document is a press release announcing Uni-Bio Science Group’s 2025 annual financial results, with key highlights such as revenue, profit, EPS, dividends, and business updates. It is not the full Annual Report (10-K) with complete financial statements, nor a report publication announcement. It fits the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-03-27 English
Uni-Bio Science Joins Forces with WMU NERC and Ouhai District Government to Build Growth Factor Innovation Ecosystem and Accelerate Regenerative Medicine Strategy Layout
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic partnership between Uni-Bio Science Group, Wenzhou Medical University, and the Ouhai District Government. It details the nature of the collaboration, the goals of the joint innovation laboratory, and the strategic implications for the company's R&D pipeline. As it does not fit into specific categories like financial results, dividends, or board changes, and is a general corporate announcement disseminated via a newswire service, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for general corporate news.
2025-12-30 English
Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine
Regulatory Filings Classification · 100% confidence The document is a corporate press release announcing a strategic shift in the company's business model, new corporate vision, and the launch of a new website. It does not constitute a formal financial report, audit, or regulatory filing, but rather a general corporate announcement regarding business strategy and communications. As it does not fit into specific categories like 10-K, IR, or ER, it falls under the general regulatory/corporate announcement category.
2025-11-24 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.